Skip to main content
main-content

Expert opinion

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.


Concise and thought-provoking commentary, opinion and analysis from leading rheumatology experts.

Enhancing clinical assessment with ultrasonography in juvenile idiopathic arthritis

Figure 2

Johannes Roth outlines the rationale behind the use of musculoskeletal ultrasonography in children with juvenile idiopathic arthritis, including enhancement of clinical assessment as part of a treat-to-target approach.

The microbiota in juvenile idiopathic arthritis: What’s wrong, and what can we do?

Intestinal villi- microbiome

In this editorial, Matthew Stoll explores the role of the microbiota in the pathogenesis of juvenile idiopathic arthritis, as well as current research into therapeutic alterations of the microbiome.

Osteoporosis therapy: Drug holiday or not?

Osteoporosis (illustration)

Malachi McKenna explains the risks of long-term bisphosphonate therapy in patients with osteoporosis, and the rationale for a drug holiday. He also compares bisphosphonates with denosumab, and explains why denosumab should not be followed by a drug holiday.

Cardiovascular risk management in arthritis: Why still a bridge too far?

Cardiovascular disease (illustration)

Cardiovascular disease is the main cause of death in patients with rheumatoid arthritis. In this editorial Michael Nurmohamed discusses the EULAR recommendations for cardiovascular risk management, focusing on the role of the rheumatologist.

20 years of TNF inhibitors in rheumatoid arthritis

Antibodies (illustration)

Understanding and treatment of rheumatoid arthritis has changed dramatically over the past two decades. Peter Taylor describes the impact of biologic tumor necrosis factor inhibitors on the management of this disease.

18-03-2019 | Juvenile idiopathic arthritis | Editorial | Article

Enhancing clinical assessment with ultrasonography in juvenile idiopathic arthritis

Johannes Roth outlines the rationale behind the use of musculoskeletal ultrasonography in children with juvenile idiopathic arthritis, including enhancement of clinical assessment as part of a treat-to-target approach.

01-03-2019 | Juvenile idiopathic arthritis | Editorial | Article

The microbiota in juvenile idiopathic arthritis: What’s wrong, and what can we do?

In this editorial, Matthew Stoll explores the role of the microbiota in the pathogenesis of juvenile idiopathic arthritis, as well as current research into therapeutic alterations of the microbiome.

18-02-2019 | Osteoporosis | Editorial | Article

Osteoporosis therapy: Drug holiday or not?

Malachi McKenna explains the risks of long-term bisphosphonate therapy in patients with osteoporosis, and the rationale for a drug holiday. He also compares bisphosphonates with denosumab, and explains why denosumab should not be followed by a drug holiday.

12-02-2019 | Cardiovascular disease | Editorial | Article

Cardiovascular risk management in arthritis: Why still a bridge too far?

Cardiovascular disease is the main cause of death in patients with rheumatoid arthritis. In this editorial Michael Nurmohamed discusses the EULAR recommendations for cardiovascular risk management, focusing on the role of the rheumatologist.

11-02-2019 | Rheumatoid arthritis | Editorial | Article

20 years of TNF inhibitors in rheumatoid arthritis

Understanding and treatment of rheumatoid arthritis has changed dramatically over the past two decades. Peter Taylor describes the impact of biologic tumor necrosis factor inhibitors on the management of this disease.

29-01-2019 | Lupus nephritis | Editorial | Article

Emerging therapies for lupus nephritis

Lupus nephritis is the most common organ-threatening complication of systemic lupus erythematosus, and current treatment regimens are only partially effective and are potentially toxic. In this editorial, the authors focus on emerging therapeutics to treat this disease.

11-01-2019 | Psoriatic arthritis | Editorial | Article

Screening psoriasis patients for development of psoriatic arthritis

Vinod Chandran discusses recent developments in screening tools for identifying patients with psoriatic arthritis, and those who are at high risk for developing this disease.

14-11-2018 | Infection | Editorial | Article

Minimizing infection risk with biologic therapy

While the development of biologics has revolutionized treatment of rheumatic diseases, these agents can lead to immunosuppression and increased infection risk. Eoin Feeney discusses the role of screening and treatment for latent infection prior to therapy, vaccination timing, and travel risks in patients taking these medications.

18-10-2018 | Microbiome | Editorial | Article

Why every rheumatologist should understand the microbiome

James Rosenbaum and Mark Asquith discuss how the microbiome interacts with the immune system, how this may induce inflammation, and how the microbiome could be used as a therapeutic target for rheumatic diseases.

18-10-2018 | Infection | Editorial | Article

Vaccination in children and adolescents with rheumatic conditions

In this editorial, the authors discuss the risks of live vaccination in children taking antirheumatic medications and how to manage these, as well as how health authorities can address decreasing vaccination coverage of the general public.

image credits